# The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma

> **NCT07290010** · PHASE2 · RECRUITING · sponsor: **Hebei Medical University Fourth Hospital** · enrollment: 25 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma (ESCC)

## Interventions

- **DRUG:** Iparomlimab and Tuvonralimab combined with chemotherapy

## Key facts

- **NCT ID:** NCT07290010
- **Lead sponsor:** Hebei Medical University Fourth Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2026-12
- **Final completion:** 2028-06
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2025-12-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07290010

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07290010, "The Efficacy and Safety of Iparomlimab and Tuvonralimab Injection Combined With Chemotherapy as the First-line Treatment for Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT07290010. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*